[Form 4] IBEX Ltd Insider Trading Activity

Rhea-AI Filing Summary

Form 4 shows that Christina Trofimuk-O'Connor, Chief Legal Officer of IBEX Ltd (IBEX), reported a sale of 844 common shares on 09/16/2025 at a price of $38.50 per share. After the reported transaction she beneficially owns 11,727 shares, held directly. The filing was made as a single reporting person and signed by an attorney-in-fact on 09/17/2025.

Positive

• Transparent disclosure of the insider sale, including transaction date, price, and post-transaction holdings
• No derivative or complex transactions reported—only a straightforward non-derivative sale

Negative

• Insider disposition of 844 shares reduces the officer's direct holdings to 11,727 shares
• No contextual explanation for the sale provided in the form

Insights

Securities Analyst

TL;DR: Officer sold a modest block of shares, reducing direct holdings to 11,727 shares.

The reported sale of 844 shares at $38.50 is a routine insider disposition and represents a small percentage of the officer's total direct holdings as reported. There are no derivative transactions disclosed and no indications of coordinated group filings. For investors, this form provides transparency on insider liquidity but does not, by itself, indicate a material change to ownership structure.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 reporting of an officer's share sale; no other governance actions noted.

The form identifies the reporting person as an officer (Chief Legal Officer) and reports a single non-derivative sale. The filing format and signature by attorney-in-fact meet procedural requirements. There are no related-party transfers, option exercises, or amendments in this submission.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Trofimuk-O'Connor Christina Alice

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/16/2025		S		844	D	$38.5	11,727	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IBEX (IBEX) insider Christina Trofimuk-O'Connor report on Form 4?

She reported a sale of 844 common shares on 09/16/2025 at $38.50 per share and now beneficially owns 11,727 shares directly.

Does the Form 4 for IBEX show any option exercises or derivative transactions?

No. Table II for derivative securities contains no entries; the filing reports only a non-derivative common share sale.

Who filed the Form 4 for the IBEX insider and when was it signed?

The form indicates it was filed by one reporting person and was signed by an attorney-in-fact, Lisa Lenstrohm, on 09/17/2025.

How many shares does the reporting officer own after the transaction?

After the reported sale the officer beneficially owns 11,727 common shares (direct ownership).

Is there any amendment or additional explanation included in the Form 4?

The form shows no amendment date and contains no explanatory remarks beyond the standard signature block.